Trimetrexate efficacy and pharmacokinetics during treatment of refractory Pneumocystis carinii pneumonia in an infant with severe combined immunodeficiency disease

Pediatr Infect Dis J. 1990 Mar;9(3):212-4; discussion 215. doi: 10.1097/00006454-199003000-00014.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / pharmacokinetics*
  • Antifungal Agents / therapeutic use*
  • Drug Combinations / pharmacokinetics
  • Drug Combinations / therapeutic use
  • Glucuronates / pharmacokinetics*
  • Glucuronates / therapeutic use*
  • Humans
  • Immunologic Deficiency Syndromes / complications*
  • Infant
  • Infusions, Intravenous
  • Leucovorin / therapeutic use
  • Male
  • Pentamidine / therapeutic use
  • Pneumonia, Pneumocystis / complications
  • Pneumonia, Pneumocystis / drug therapy*
  • Quinazolines / pharmacokinetics*
  • Quinazolines / therapeutic use*
  • Respiratory Insufficiency / complications
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Trimetrexate* / analogs & derivatives*

Substances

  • Antifungal Agents
  • Drug Combinations
  • Glucuronates
  • Quinazolines
  • Pentamidine
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • trimetrexate glucuronate
  • Leucovorin
  • Trimetrexate